Current Pharma Research
ISSN-2230-7842
CODEN-CPRUE6
www.jcpronline.in/

Review Article

Cancer: Clinical Trials and Their Mechanism of Action.

Uday Raj Sharma*, Abhishek Raj Joshi, Kamrudeen Samani, Surendra V., Manjunath P.M., Gurubasvaraja Swamy

Acharya & BM Reddy College of Pharmacy, Soladevanahalli, Hesaraghatta main road, Achit Nagar Post Bengaluru-560107, India.

Received 01 January 2020; received in revised form 22 February 2020; accepted 28 February 2020

***Corresponding author E-mail address:** *sharma.uday1@gmail.com*

ABSTRACT
Cancer is those types of disease that can affects any parts of the body in which there is uncontrolled growth of the cells and may or may not invade its neighboring cells on the basis of their nature. Till now it is very difficult to cure the cancer due to lack of the early detection and also inefficacy of the target oriented treatment. But among the others types of the treatment the most effective treatment is of triple therapy including tumor surgery and platinum based chemotherapy along with the dose of bevacizumab. Also the chalcones therapy is found to be the effective one because of the maximum target sites on the body with the help of several pathways some of them is stated below.

KEYWORD
Chalcones, Tumor, Cancer, PARP, P53, microtubules.

1. INTRODUCTION

Malignancy is a non-exclusive disease that can affect any parts of our body. Tumors and neoplasms are threatened by various terms used. Another characterizing highlight of malignant growth is the massive growth of anomalous cells that develop beyond their normal limits. It can target connecting parts of the body and spread to various organs. The last step is referred to as metastasizing. Metastasis is a significant cause of malignant death. Cancer is the major cause of the death universally and is responsible for the expected passing of 9.6 million in 2018. All inclusive, around 1 out of 6 is due to malignant growth Around 70 % of cancer deaths occur in low and middle income countries.

About 33 % of malignant growth transfers are attributed to 5 driving behaviour and dietary dangers: high weight loss, low soil intake goods, lack of physical action, use of tobacco and liquor use. [1] The use of tobacco is the most significant potential risk for malignant growth and accounts for roughly 22% of disease transfers. [2] Cancer that provokes inflammation, like hepatitis and infection with human papilloma (HPV), accounts for up to 25 % of malignant growth in low and centre paying nations. [3] It is normal to implement late plans and find and care difficult to achieve. In the year of 2017, just 26 % of low-paid nations reported widely available pathology benefits in the open division. In contrast to very little than 30 % of low paid nations, over 90 % of high salary nations with detailed care administrations are accessible. The disease's monetary effect is huge and gradually is rising. The total yearly monetary expense of malignant growth in 2010 was estimated at nearly US$ 1.16 trillion. [4] Only one out of five low and centre wage nations has the basic information to drive malignant growth. [5]

Perplexity

Worldwide, Cancer could be a leading cause of death for 9.6 million deaths in the year of 2018. The foremost common cancers are Prostate, Lung, Colorectal, Skin cancer, Breast, Stomach etc. Among them most prevalent cancer causing death are Lung, Colorectal, Stomach, Liver and Breast cancer.

Programmes conducted by the WHO for cancer

During the year of 2017, the World Health Assembly (WHA) passed an Integrated Approach to Cancer Prevention and Control Resolution (WHA70.12) calling on governments and the WHO to speed up action to achieve the objectives outlined out in the Global Action Plan and 2030 UN Sustainable Development Agenda to minimize premature cancer mortality.

- WHA70.12: Cancer prevention and control in the context of an integrated approach
- Global action plan for the prevention and control of NCDs 2013-2020

Chalcone is the drug that is used to treat cancer. Chalcone is an associated degree of organic aromatic compound. It forms the core for the spread of the necessary biological compounds, legendary together as chalcones or chalconoids. The parent member of the chalcone group is benzylideneacetophenone. The alternative name given to chalcone is the organic compound of phenyl styryl, benzalacetophhenone, β-phenylacrylophhenone, π-oxo-α, π-diphenyl-α-propylene,

and α-phenyl-β-benzoylethylene. Chalcones and their derivatives demonstrate wide selection of biological activities benefical for anti-inflammation, anti-cancer and so on.

Chalcones may be ready by an organic compound condensation between benzaldehyde and acetophenone within the presence of sodium hydroxide as a catalyst.



Fig. 1. Synthesis of chalcone derivatives.

Derivatives are ethoxy, methoxy and nitro compounds

As per the International agency for research on Cancer (IARC) on September 12, 2018 Geneva, Switzerland the global cancer burden had risen to 18.1 million and the death due to the cancer has estimated to be 9.6 million.

Nowadays, in the era of precise medicine analysis of biological characteristics and their MOA, we have been led to predict other stimuli that can manipulate treatment effects resulting in platinum sensitive and platinum resistance. [6]

Some of the novel predictive biomarkers of response are:

1. Breast related cancer antigen (BRCA)
2. Homologous recombinant deficiency (HRD)
3. Poly adenosine di-phosphate (ADP) ribose polymerase(PARP's) inhibitor (PARPis) treatment

1.2. Treatment by multiple therapy

In between Dec 18, 2006 to February 16, 2009, 7 GCIG arrays screened 1528 females with malignant ovarian growth from below 263 bend-sectional concentrate across Europe, Canada, Australia and New Zealand. They are recruited and randomly administered generic carboplatin and paclitaxel chemotherapy (n=764) or other standard chemotherapy drugs in addition to bevacizumab (n=764). The intermediate visiting was done in 48.9 months. Calm benchmark characteristics are laid out in file p 8, which is 57 years age of patients (IQR 50–64); 1415 (94%) of 1501 (despite those with dark execution status) had an ECOG execution status of 0 or 1; 1340 (89%) of the 1502 population (banning those with harmful development from different areas) had a dangerous development of ovarian reason; 1054 (69%) had a dangerous histology problem.; 175 (11%) had FIGO classified III, IIIA or IIIB disease and 1071 (70%) had either IIIC or IV disease. 395 (26%) patients had a remaining infection greater than 1 cm, 369 (24%) had an apparent range of up to 1 cm, and 734 (48%) had no apparent remaining infection.Each and every randomized patient is remembered for investigations and attributes of understanding were adjusted as one of the gatherings all around (informative supplement p 8). Middle visits

were conducted 48.6 months (IQR 24.3–56.0) in the generic chemotherapy sample and 48.8 months (28.2–56.4) in the bevacizumab collection with shorter visit intervals of 29.0 months (14.1–50.7) in addition to 38.9 months (21.1–52.5) in the case of high-chance patients. The patient subgroup of steep-risk consists of 1528 patients (33 %). A middle age was 60 (IQR 52–66) and 60 (12%) had an evident peritoneal starting point malignancy (compared to 106 [7%] of all enrolled patients in general). A significant proportion of high-chance patients (381[76%]) had serous-type ovarian malignancy, with 30 (6%) patients not having a debunking medical procedure. In net gain, 714 patients (47%) went through the investigation: 352 (46%) in the entire chemotherapy package and 362 (47%) in the chemotherapy range in addition to bevacizumab selection. [7]

1.3. Pathway of Chalcone in Case of Cancer Cells

1.3.1. Poly ADP ribose polymerase and ADP ribose polymerase inhibitors pathway

PARPs are a group of 17 nucleoproteins, commonly known as synergistic sites that transfer the ADP-ribose bunch on the particular acceptor protein using NAD+ as a cofactor. Generally speaking, PARP individuals are fit to move only a mono-ADP ribose to their objective proteins, although PARA1, PARP2, PARP3 PARP5a and PARP5b naturally include rehashed ADP ribose units that cause long poly age (ADP ribose) (PAR) chain. [8] This modification of the post-interpretation protein is otherwise called PARylation and also helps to contribute to PARPs in a few cell movements. PARP1 is highly defined among all PARPs that can change the structure of chromatin by enabling replication fixation and interpretation of the center histone protein driving chromatin unwinding. [9]

PARP1 assumes a crucial role in its guidance during interpretation, both by filling in as a transcriptional cofactor and by blocking methylation of explicit successions.Until now, the activation of the CCCTC-based PARP1 limit variable [CTCF] seems to influence DNA methylation along these lines, suggesting a close association between DNA methylation and PARylation.

Chromatin modification (CTCF)

-PARylation of histone proteins, CTCF, DNHT1, direct association.

CTCF is an exceptionally secure chromatin protector that links to explicit agreement successions located on the gravure control area, thereby preventing recurrent methylation.On the basis of ongoing examinations, CTCF may initiate PARP1 itself to specify ADP ribosylation of DNA (cytosine-5)-methyl transferase-1 (DNTM1) and its residence. [10]

a) Regulation of transcription:
Direct interaction: Cox-2, Oct-1, E2f-1, AP2
PARylation: P53, RNA pol I, RNA pol II
Both: NFKB

b) Cell death:
-energy crisis (NAD/ATP depletion)
-JNK, BAX, cathepsin/calpain

The component that passes the cell is also interested in PAPR1. The consumption of ATP and NAD is brought about when elevated levels of DNA harm occur due to maturation, stress and disease over PARP1 action.This vitality emergency prompts an intricate interaction between C-jun N-terminal kinase (JNK), the Bax mitochondrial protein, and cithepsin / calpain protease, resulting in apoptosis rift including factor (AIF).

Once in its core AIF builds a DNA-debased complex with H2AX and cyclophilin A, forming a controlled rot called Parthanatos. [11]

c) Inflammation:

NFKB

↓

ROS, TNF-α, IL6, iNOS

However, by integrating the kappa-light-chain-enhancer atomic factor of the initiated B cell (NFKB) translation factor, PARP1 advances the assertion of such suggestive qualities as IL6 and TNF-α. [12]

d) DNA repair (BER):



PARP1, PARP2 and PARP3 catalyze PARylation during the DNA damage reaction. Due to the normal and indogenous stress human qualities, enduring sores and damage including breaks of single-strand DNA-binding protein (SSB) and double-strand DNA-binding protein (DSB) have always been discovered.Base extraction break (BER) is the main fixed SSB pathway whereas homologous recombination (HR) and non-homologous end joining (NHEJ) is the principle of DSB fixing machinery in the cells.PARP1 distinguishes and binds the Zinc finger to SSB using space-restricting methods. This association prompts conformity changes, which in effect allosterically initiates the PARP1.Thus atomic protein PARylation such as topoisomerase, DNA ligase III, DNA polymerase β, and platform proteins (e.g. XRCC1) occurs at DNA break destinations. Auto PARylation procedure is responsible for releasing PAR1 from DNA by restoring its chemically dormant state (' string dots ' adaptation). [13]

Despite the fact that, less is known about the contribution of PARP2 and PARP3 to the harmful DNA reaction. PARP2 is known to be coupled to the BER / SSB fixed pathway, while PARP3 is linked to the DSB fix via the NHEJ pathway. [14]

PARP1 also helps the hour system clinically by recruiting very important deoxyribonucleic acid repair factors such as NSB1 and MRE11 DSB sites and preventing Ku70/80 from binding DNA

injury areas. Ku protein is an essential component of the NHEJ pathway, and PAR1 plays a key role in its inhibition. [15]

Instead, HR predominates throughout the cell cycle's mid- and mid-phase synthesis as a repair mechanism and requires useful BRCA proteins to repair DSBs.BRCA1 plays a complete role in the deoxyribonucleic acid interaction and in the command point regulation of the cell cycle, while BRCA2 plays a major role in the restoration of deoxyribonucleic acid by the dominant operation and assembly of the RAD51 recombination accelerator. [16]People with harmful BRCA mutations have a median accumulative risk of developing OC at age 70 between 39 and 60 %; harmful BRCA1 mutations and BRCA2 deficiency can be estimated as 11-30%. [17] A PARP1 interruption result in SSB fixing irritation in any cell, but it does not affect repairing DSB. Off chance that BRCA proteins in a similar cell are also insufficient DBSBs are fixed along these lines by the NHEJ process leading to chromosomal flimsiness, cell cycle capture, and apoptosis.This is a descriptive case of what the so-called "manufactured lethality" is, i.e. the situation where a deformity in both qualities has practically zero impact when their blend (BRCA and PARP qualities) causes distress (engineered infection) or even passing (engineered lethality). Two preclinical examinations [12, 18] distributed in 2005 exhibited that BRCA1 and BRCA2-freak cells and xenografts are profoundly delicate to PARP inhibitors (PARPis), in this manner giving solid help to their clinical improvement. PARPis is initially created to potentiate anti-tumor movement by ionizing radiation and genotoxic specialists (temozolomide and topotecan).Yes; both PARPs are consistent with their capacity to repress DNA harm in vitro and in vivo radio or chemo. The behavioural mechanism of PARPis is associated not only with the restriction of PARP synergistic action, but also with an allosteric conformational transition that settles the PARP1-PARP2 relationship with DNA. The abilityto catch PARP-DNA complex clarifies the different size of cytotoxicity applied by different PARPis.[19]



Fig. 2. MOA of PARPs and PARPs inhibitors.

1.3.2. P53 pathway

The role of the P53 is the guardian of the genome. It is an endogenous tumor suppressor's active agent. In response to oncogene activation damage and other cell stress signals, it can mediate numbers of varied biological effects such as cell senescence, cell cycle arrest, apoptosis, etc. The loss of P53 functions occurs in most human cancer tumors either by mutation itself or by inactivation of the P53 gene signal transduction pathway. Mutation is found in large numbers of human cancer. P53 is inactivated by over expression of the negative regulator, particularly MDM2.

Mini atoms that suppress P53/MDM2 cooperation may reactivate the P53 disease pathway, thereby ensuring protesomal corruption of P53. As of now, two mixtures of MDM2 inhibitors (JNJ-26854165, Johnson and Johnson and RG7112, F. Hoffmann–La Roche) are being studied in stage I clinical preliminaries in patients with hematological neoplasms and heavy tumors are being propelled. [20, 21]

Chalcones were among the top of the line of exacerbates demonstrating action in governing the interaction p53/MDM2.Stoll and colleagues used multidimensional NMR spectroscopy, an ELISA test that used a p53 peptide and a gel movement analysis, were the first to announce that the chalcones were bound to MDM2 at the transactivation space p53, resulting in the arrival of p53 from both the p53/MDM2 and the p53/MDM2 DNA-bound buildings. [22]

Based on this data from the NMR, Kumar *etal.*, [23] conjectured that the chalcones ' carboxylic corrosive array could be placed near the base of K51 lysine to frame a salt extension and then split the salt scaffold connecting with Glut25 in the p53/MDM2 complex. Kumar *et al*., [23] therefore structured and incorporated a progression of boronic corrosive chalcone analogs that could frame a more grounded salt scaffold with K51 lysine than the corrosive analogs of the carboxylic. We observed that these boronic chalcones at low μM range were 5–10 overlays that were progressively harmful to human chest harmful development cell lines appeared differently from conventional chest epithelial cell lines. From a similar group, Modzelewska *et al*., [24] have arranged another class of chalcones (bischalcones) with a few α, β-unsaturated gatherings. A portion of these chalcones in particular repressing the progress of bosom malignant growth cell lines were very progressively strong Another bis-chalcone demonstrated differential cytotoxicity to an isogenic pair of HCT116 cells of colon disease; p53+/+ cells were increasingly prone to contrasting bis-chalcone and p53−/− cells.

Hsu *et al*., [25] further demonstrated that the effect of isoliquiritigin (4, 2', 4'-trihydroxychalcone) on the production of Hep G2 can be reduced by an overwhelming negative p53 that squares the transcriptional action of p53. In any case, the effect of these chalcones on p53/MDM2 contact was not directly discussed by these tests. In total, these outcomes recommend that restraint of the MDM2/p53 association may not be the essential anticancer component of chalcones. As a rule, selectivity was shown against the development of malignant growth cells versus ordinary cells by a large portion of chalcones. Many chalcones (e.g. Hydroxysafflor yellow AHSYA and imidazolechalcone) [26-28] seemed to build the outflow of p53 and explicitly limited the production of wild-type p53 malignant cells, while other chalcones

[e.g.]. Toluenesulfonylamido-chalcone, 4′-(p-toluene sulfonyl amino)-3,4-dihydroxy chalcone (TSHDC)] has been reported to lessen p53. We demonstrated that flavokawain An, a chalcone isolated from Kava, specifically hindered the creation of p53 freak bladder malignant growth lines and their effect on cell cycle capture vary in p53 wild and freak type bladder disease cell lines. Flavokawain A contributed to the capture of G1 in RT4 cells possessing wild type p53 and G2 M in the bladder with freak p53. [29]

In the UPII-SV40 T transgenic model, they also reported that dietary flavokawain an oddly restricted urothelial tumorigenesis in vivo that looks like human urothelial cell carcinoma (UCC) with imperfections in the p53 and the protein pathways of retinoblastoma (RB). [30]

Together, these investigations suggest that chalcone's different compound structures that add to their differential impacts associated with the p53 pathway. The effect of Chalcone systems in malignant growth cells on the p53 pathway. Through a precise investigation of their structure-association with freak p53 cells, there is a potential chance to discern certain chalcones that react to the tumor stifling pathway.



Fig. 3. Chalcones target the p53 pathway.

1.3.3. Tubulin polymerization pathway

The use of chalcones as antimitotic specialists was first announced about 20 years before and refers to the timeliest trials of chalcones as restorative operators. [31]

In enhancing the learning of colchicine-tubulin structure-action relations, chalcone subsidiaries were presented as colchicine analogous to achieve a tubulin-restricting site comparative reactivity, leading microtubules to be overthrown. Structural movement connections were then concentrated as controls with colchicine and vinblastine (known tubulin-restricting antimitotic specialists) from a vast number of chalcone subsidiaries.



Fig. 4. Chalcones target tubulin polymerization.

A range of chalcones that is analogous to combretastatin 4A, like SD400 and MDL, certainly have an analogous ability to bind β-tubulin and thus vary IC50s within the low micromolar. Ducki *et al*. obviously considered antimitotic action to be significantly related to the degree of methoxylation. [32-34]

These candidates were tested in vitro and are found in animal models to be non-toxic. Zoldakova *et al.,* [35] jointly reported on combretastatin-like chalcones and classified as a candidate exhibiting marked tubular disruption and cell cycle arrest in 512A cells and neural cells of malignant melanoma.the same polymers of tubulin tubules. Ducki *et al*.[32-33] presented a radical review of alpha-aryl chalcone derivatives, the structure-activity relationship of which studies incontestable each antimitotic properties (IC50s in the low micromolar range) in K562 leukaemia cells with G2/M arrest, as well as antiviral activity. Boumendjel *et al*., [34] have equally synthesized a library of chalcones and known three candidates showed significant antimitotic activity, with -binding mechanism at play once more.In addition, this same cluster of investigators imposes a purposeful Pt complicated on the p arent chalcone, rendering the tubulin chemical process effects more cytotoxic by inserting DNA adduct effects. [36] Ruan *et al*., [37] synthesized a series of chalcone resveratrol derivatives and reported that these compounds reduced the expansion of neoplastic cell lines by binding them to the tubulin-colchicine binding database, inhibiting tubulin polymerization and inducing G2 M arrest throughout the progression of the cell cycle. Based on the similarity of chalcone's chemical structure with combretastatin and their simple chemical modification, chalcones are a

highly engaging beginning material for synthesizing novel agents that target tubulin for cancer treatment.

2. CONCLUSION

Cancers may be treated by the various ways i.e. the multiple treatment therapy and by the helps of the chalcones which has several pathway to stop the cancer cells by the several pathway at very early stage. Since the chalcones has several targeted sites on the body like blocking MDM2 for the formation of the complex which lead to the disturbance of the normal apoptosis for the damaged and altered cell forming the cancer cell immortal resulting in the cell death, it also act by inhibiting the PARP causing the energy crisis which are needed for the cells for regular activity and metabolism and also by the destabilization of the microtubules during the cell division to restrict their growth and development. So it may be effective in the treatment of the different kinds of the cancers cell like breast cancer, ovarian cancer and lungs cancer also. These data shows some ways to treat the cancer but there are also lots of pathway which should be needed to treat the cancer along with the complications seen after the treatment.

3. ACKNOWLEDGEMENT

The authors are thankful to Principal and the Management of Acharya and BM Reddy College ofPharmacy, Bengaluru, for extending their cooperation and providing us with necessary supportfor preparing this review article.

4. CONFLICT OF INTEREST

There aren't any conflicts of interest related to this publication

5. REFERENCES

1. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., et al. (2013). Cancer Incidence and Mortality Worldwide: IARC Cancer Base No.11 Lyon, GLOBOCAN 2012 v1.0. France: International Agency for Research on Cancer.
2. Forouzanfar, MH.et al.(2016).Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study. *The Lancet.* 388(10053),1659-724.
3. Plummer, M., de Martel, C., Vignat, J., Ferlay, J., Bray, F., Franceschi, S. (2016). Global burden of cancers attributable to infections in 2012: a synthetic analysis. *Lancet Glob Health.* 4(9),e609-16. Doi: 10.1016/S2214-109X(16)30143-7.
4. Stewart, B.W., Wild C.P.(2014). World cancer report 2014 Lyon: International Agency for Research on Cancer.
5. Global Initiative for Cancer Registry Development. International Agency for Research on Cancer, Lyon: France.

6. Venkitaraman, A.R.,(2014) Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. *Science.* 343,1470–5. https://doi.org/10.1126/science.1252230.

7. Oza, A.M., Cook A.D., Pfisterer, J., Embleton, A., Ledermann, J.A., Pujade-Lauraine, E., et al. (2015). Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. *Lan1cet Oncol.* 16,928–36. https://doi.org/10.1016/S1470-2045(15) 00086-8.

8. Barkauskaite, E., Jankevicius, G., Ahel, I. (2015). Structures and mechanisms of enzymes employedin the synthesis and degradation of PARP-dependent protein ADP-ribosylation. *Mol Cell*.58,935–46. https://doi.org/10.1016/j.molcel.2015.05.007.

9. Bryant, H.E., Schultz, N., Thomas H.D., Parker, K.M., Flower, D., Lopez, E.et al.(2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature.* 434, 913–7. https://doi.org/10.1038/nature03443.

10. Calabrese, C.R., Almassy, R., Barton, S., Batey, M.A., Calver,t A.H., Canan-Koch, S., et al. (2004). Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose)polymerase-1 inhibitor AG14361. *J Natl Cancer Inst.* 96, 56–67.

11. Murai, J., Huang, S.N., Das, B.B., Renaud, A., Zhang, Y., Doroshow, J.H.et al. (2012). Trapping of PARP1 and PARP2 by clinical PARP inhibitors. *Cancer Res.* 72,5588–99. https://doi.org/10.1158/0008-5472.CAN-12-2753.

12. Zhang, S., Royer, R., L,i S., McLaughlin, J.R., Rosen, B., Risch, H.A., et al. (2011). Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. *Gynecol Oncol.* 121,353–7. https://doi.org/10.1016/j.ygyno. 2011.01.020.

13. Lee, A.S.G., Ang, P. (2014). Breast-cancer risk in families with mutations in PALB2. *N Engl J Med.*371,1650–1. https://doi.org/10.1056/NEJMc1410673.

14. Loveday, C., Turnbull, C., Ruark, E., Xicola, R.M.M., Ramsay, E., Hughes, D., et al.(2012). Germline RAD51C mutations confer susceptibility to ovarian cancer. *Nat Genet.*44:475–6. https://doi.org/10.1038/ng.2224.

15. Li, S. (2009). Inhibition of poly(ADP-ribose) polymerase in BRCA mutation carriers. *N Engl J Med.* 361, 17071707–8. https://doi.org/10.1056/NEJMc091621. authorreply.

16. Tabernero, J., Dirix, L., Schoffski, P., Cervantes, A., Lopez-Martin, J.A., Capdevila, J., et al. (2011). A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. *Clin Cancer Res.* 17, 6313–6321. [PubMed: 21831953]

17. Ding, Q., Zhang, Z., Liu, J.J., Jiang, N., Zhang, J., Ross, T.M., et al. (2013). Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development. *J Med Chem.* [Epub ahead of print].

18. Kumar, S.K., Hager, E., Pettit, C., Gurulingappa, H., Davidson, N.E., Khan, S.R. (2003). Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. *J Med Chem.* 46, 2813–2825. [PubMed: 12825923]

19. Modzelewska, A., Pettit, C., Achanta, G., Davidson, N.E., Huang, P., Khan, S.R. (2006). Anticancer activities of novel chalcone and bis-chalcone derivatives. *Bioorg Med Chem.* 14, 3491–3495. [PubMed:16434201]

20. Taberner, J., Dirix, L., Schöffski, P., Cervantes, A., Lopez-Martin, J.A., Capdevila, J., et al. (2011). A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. *Clin Cancer Res.* 17, 6313–6321. [PubMed: 21831953]

21. Ding, Q., Zhang, Z., Liu, J.J., Jiang, N., Zhang, J., Ross, T.M., et al. (2013). Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development. *J Med Chem.* [Epub ahead of print].

22. Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., et al. (2001). Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. *Biochemistry.* 40, 336–344. [PubMed: 11148027]

23. Kumar, S.K., Hager, E., Pettit, C., Gurulingappa, H., Davidson, N.E., Khan, S.R.(2003). Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. *J Med Chem.* 46, 2813–2825. [PubMed: 12825923]

24. Modzelewska, A., Pettit, C., Achanta, G., Davidson, N.E., Huang, P., Khan, S.R. (2006). Anticancer activities of novel chalcone and bis-chalcone derivatives. *Bioorg Med Chem.* 14, 3491–3495. [PubMed:16434201]

25. Hsu, Y.L., Kuo, P.L., Lin, C.C. (2005). Isoliquiritigenin induces apoptosis and cell cycle arrest through p53-dependent pathway in Hep G2 cells. *Life Sci.* 77, 279–292. [PubMed: 15878356]

26. Lian, Z.Q., Zhao, D.L., Zhu, H.B. (2008). Hydroxysafflor yellow A up-regulates HIF-1alpha via inhibition of VHL and p53 in Eahy 926 cell line exposed to hypoxia]. *Yao XueXueBao.* 43, 484–489. In Chinese. [PubMed: 18717335]

27. Kamal, A., Dastagiri, D., Ramaiah, M.J., Reddy, J.S., Bharathi, E.V., Srinivas, C., et al. (2010). Synthesis of imidazothiazole-chalcone derivatives as anticancer and apoptosis inducing agents. *Chem Med Chem.* 5, 1937–1947. [PubMed: 20836120]

28. Zhang, Y., Srinivasan, B., Xing, C., Lu, J. (2012). A new chalcone derivative (E)-3-(4-methoxyphenyl)-2-methyl-1-(3, 4, 5-trimethoxyphenyl) prop-2-en-1-one suppresses prostate cancer involving p53-mediated cell cycle arrests and apoptosis. *Anticancer Res.* 32, 3689–3698. [PubMed:22993307]

29. Tang, Y., Simoneau, A.R., Xie, J., Shahandeh, B., Zi, X. (2008). Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53. *Cancer Prev Res (Phila Pa).*1,439–451.

30. Liu, Z., Xu, X., Li, X., Liu, S., Simoneau, A.R., He, F., et al.(2013). KAVA chalcone, Flavokawain A, inhibits urothelialtumorigenesis in the UPII-SV40T transgenic mouse model. *Cancer Prev Res(Phila).* 6, 1365–1375. [PubMed: 24121102]

31. Peyrot, V., Leynadier, D., Sarrazin, M., Briand, C., Rodriquez, A., Nieto, J.M., Andreu, J.M.(1989). Interaction of tubulin and cellular microtubules with the new antitumor drug

MDL 27048.A powerful and reversible microtubule inhibitor. *J Biol Chem*. 264, 21296–21301. [PubMed: 2592375].

32. Ducki, S., Mackenzie, G., Greedy, B., Armitage, S., Chabert, J.F., Bennett, E., et al. (2009). Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones. *Bioorg Med Chem.* 17, 7711–7722.[PubMed: 19837594]

33. Ducki, S., Rennison, D., Woo, M., Kendall, A., Chabert, J.F., McGown, A.T., Lawrence, N.J. (2009). Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity. *Bioorg Med Chem.* 17, 7698–7710. [PubMed:19837593]

34. Boumendjel, A., Boccard, J., Carrupt, P.A., Nicolle, E., Blanc, M., Geze, A.,et al. (2008). Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship. *J Med Chem.* 51, 2307–2310. [PubMed: 18293907]

35. Zoldakova, M., Kornyei, Z., Brown, A., Biersack, B., Madarasz, E., Schobert, R. (2010). Effects of a combretastatin A4 analogous chalcone and its Pt-complex on cancer cells: A comparative study of uptake, cell cycle and damage to cellular compartments. *Biochem Pharmacol. Pharmacol.* 80, 1487–1496.

36. Schobert, R., Biersack, B., Dietrich, A., Knauer, S., Zoldakova, M., Fruehauf A., Mueller, T. (2009).Pt(II) complexes of a combretastatin A-4 analogous chalcone: effects of conjugation on cytotoxicity, tumor specificity, and long-term tumor growth suppression. *J Med Chem.* 52, 241–246. [PubMed: 19102652]

37. Dyrager, C., Wickström, M., Fridén-Saxin, M., Friberg, A., Dahlén, K., Wallén, E.A., et al. (2011). Inhibitors and promoters of tubulin polymerization: synthesis and biologicalevaluation of chalcones and related dienones as potential anticancer agents. *Bioorg Med Chem.* 19, 2659–2665. [PubMed: 21459004]